Literature DB >> 26359046

Illicit drug use and harms, and related interventions and policy in Canada: A narrative review of select key indicators and developments since 2000.

Benedikt Fischer1, Yoko Murphy2, Katherine Rudzinski2, Donald MacPherson3.   

Abstract

BACKGROUND: By the year 2000, Canada faced high levels of illicit drug use and related harms. Simultaneously, a fundamental tension had raisen between continuing a mainly repression-based versus shifting to a more health-oriented drug policy approach. Despite a wealth of new data and numerous individual studies that have emerged since then, no comprehensive review of key indicators and developments of illicit drug use/harm epidemiology, interventions and law/policy exist; this paper seeks to fill this gap.
METHODS: We searched and reviewed journal publications, as well as key reports, government publications, surveys, etc. reporting on data and information since 2000. Relevant data were selected and extracted for review inclusion, and subsequently grouped and narratively summarized in major topical sub-theme categories.
RESULTS: Cannabis use has remained the principal form of illicit drug use; prescription opioid misuse has arisen as a new and extensive phenomenon. While new drug-related blood-borne-virus transmissions declined, overdose deaths increased in recent years. Acceptance and proliferation of - mainly local/community-based - health measures (e.g., needle exchange, crack paraphernalia or naloxone distribution) aiming at high-risk drug users has evolved, though reach and access limitations have persisted; Vancouver's 'supervised injection site' has attracted continued attention yet remains un-replicated elsewhere in Canada. While opioid maintenance treatment utilization increased, access to treatment for key (e.g., infectious disease, psychiatric) co-morbidities among drug users remained limited. Law enforcement continued to principally focus on cannabis and specifically cannabis users. 'Drug treatment courts' were introduced but have shown limited effectiveness; several attempts cannabis control law reform have failed, except for the recent establishment of 'medical cannabis' access provisions.
CONCLUSIONS: While recent federal governments introduced several law and policy measures reinforcing a repression approach to illicit drug use, lower-level jurisdictions (e.g., provincial/municipal levels) and non-governmental organizations increasingly promoted social- and health-oriented intervention frameworks and interventions, therefore creating an increasingly bifurcated - and inherently contradictory - drug policy landscape and reality in Canada.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Canada; Epidemiology; Illicit drugs; Interventions; Policy; Review

Mesh:

Substances:

Year:  2015        PMID: 26359046     DOI: 10.1016/j.drugpo.2015.08.007

Source DB:  PubMed          Journal:  Int J Drug Policy        ISSN: 0955-3959


  9 in total

1.  Service Use and Unmet Needs for Substance Use and Mental Disorders in Canada.

Authors:  Karen Urbanoski; Dakota Inglis; Scott Veldhuizen
Journal:  Can J Psychiatry       Date:  2017-06-15       Impact factor: 4.356

2.  Applicability of a national strategy for patient-oriented research to people who use(d) substances: a Canadian experience.

Authors:  Bernadette Pauly; Ginger Sullivan; Dakota Inglis; Fred Cameron; Jack Phillips; Conor Rosen; Bill Bullock; Jennifer Cartwright; Taylor Hainstock; Cindy Trytten; Karen Urbanoski
Journal:  Res Involv Engagem       Date:  2022-05-24

3.  Association between public injecting and drug-related harm among HIV-positive people who use injection drugs in a Canadian setting: A longitudinal analysis.

Authors:  Sarah Ickowicz; Evan Wood; Huiru Dong; Paul Nguyen; Will Small; Thomas Kerr; Julio S G Montaner; M-J Milloy
Journal:  Drug Alcohol Depend       Date:  2017-08-10       Impact factor: 4.492

4.  The emergence of innovative cannabis distribution projects in the downtown eastside of Vancouver, Canada.

Authors:  Jenna Valleriani; Rebecca Haines-Saah; Rielle Capler; Ricky Bluthenthal; M Eugenia Socias; M J Milloy; Thomas Kerr; Ryan McNeil
Journal:  Int J Drug Policy       Date:  2020-04-11

Review 5.  Public health and international drug policy.

Authors:  Joanne Csete; Adeeba Kamarulzaman; Michel Kazatchkine; Frederick Altice; Marek Balicki; Julia Buxton; Javier Cepeda; Megan Comfort; Eric Goosby; João Goulão; Carl Hart; Thomas Kerr; Alejandro Madrazo Lajous; Stephen Lewis; Natasha Martin; Daniel Mejía; Adriana Camacho; David Mathieson; Isidore Obot; Adeolu Ogunrombi; Susan Sherman; Jack Stone; Nandini Vallath; Peter Vickerman; Tomáš Zábranský; Chris Beyrer
Journal:  Lancet       Date:  2016-03-24       Impact factor: 79.321

6.  Pain and Barriers to Accessing Health Services Among People Who Use Drugs.

Authors:  Pauline Voon; Linwei Wang; Ekaterina Nosova; Kanna Hayashi; M-J Milloy; Evan Wood; Thomas Kerr
Journal:  Pain Manag Nurs       Date:  2020-12-24       Impact factor: 1.929

7.  Social-structural factors influencing periods of injection cessation among marginalized youth who inject drugs in Vancouver, Canada: an ethno-epidemiological study.

Authors:  Jade Boyd; Danya Fast; Megan Hobbins; Ryan McNeil; Will Small
Journal:  Harm Reduct J       Date:  2017-06-05

8.  Opioid agonist therapy trajectories among street entrenched youth in the context of a public health crisis.

Authors:  Valerie Giang; Madison Thulien; Ryan McNeil; Kali Sedgemore; Haleigh Anderson; Danya Fast
Journal:  SSM Popul Health       Date:  2020-06-04

9.  Defining culturally safe primary care for people who use substances: a participatory concept mapping study.

Authors:  Karen Urbanoski; Bernadette Pauly; Dakota Inglis; Fred Cameron; Troy Haddad; Jack Phillips; Paige Phillips; Conor Rosen; Grant Schlotter; Elizabeth Hartney; Bruce Wallace
Journal:  BMC Health Serv Res       Date:  2020-11-23       Impact factor: 2.655

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.